FLT3LG and diffuse large B-cell lymphoma: 177Lu-lilotomab satetraxetan is currently being investigated as a single-injection mono-therapy for treatment of relapsed or refractory (r/r) FL (NCT01796171, Phase 2B) and r/r-DLBCL (NCT02658968, Phase 1), showing a promising overall response rate in r/r-FL of about 65–70% (20).